Record the type and duration of leprosy, treatment (MDT), reactions and the duration of lagophthalmos.
Examine lid closure, corneal sensation, conjunctiva, sclera, pupil and nasolacrimal system.
Exposure keratopathy and corneal anaesthesia threaten sight: protect the cornea early.
Watch for iritis, iris pearls and secondary cataract and glaucoma; educate patients on self-care.
Below Details are Adapted from the American Academy of Ophthalmology Summary Benchmarks, November 2010 (www.aao.org)
(Ratings: A: Most important, B: Moderately important, C: Relevant but not critical
Strength of Evidence: I: Strong, II: Substantial but lacks some of I, III: consensus of expert
opinion in absence of evidence for I & II)
Initial Exam History
Ocular symptoms (decreased vision, epiphora, symptoms of irritation) (A:III)
Duration of lagophthalmos (< or > 6 months) (A:III)
Duration of leprosy (usually from date of diagnosis) (B:III)
Type of leprosy (A:III)
MDT treatment; what drugs and for how long (A:III)
History of leprosy reactions (B:III)
Initial Physical Exam
Visual acuity (A:III)
Eyelids and lid closure (A:III)
Corneal sensation (A:III)
Conjunctiva (A:III)
Sclera (A:III)
Pupil (A:III)
Nasolacrimal apparatus (A:III)
Slit lamp biomicroscopy
Corneal epithelial integrity (A:III)
Corneal nerve beading, stromal opacity (B:III)
Anterior chamber (A:III)
Iris atrophy (A:III)
Iris "pearls" (B:III)
Posterior synechiae (A:III)
Cataract (A:III)
Care Management
The main important conditions (cataract, lagophthalmos, anterior uveitis) are managed as for
any patient, and people with leprosy should be integrated into the normal eye care service,
specifically:
Cataract should be removed when it adversely affects patient's visual function (A:III)
IOL is not contraindicated as long as quality of surgery is good and eye is quiet (A:III)
Chronic lagophthalmos should be treated surgically if cornea is compromised or
cosmesis is a problem, regardless of severity of lagophthalmos, by whatever procedure
the surgeon does best (A:III)
Special considerations in a person afflicted with leprosy include:
New onset lagophthalmos (duration <6 months) should be treated with oral
prednisolone 25-30 mg per day tapered over 6 months. (A:III)
Acute uveitis should be treated with intensive topical steroid; associated systemic
leprosy reaction must be ruled out or treated if present with systemic steroid give
dose) (A:III)
Patient Education
At the end of MDT all patients should be warned that lagophthalmos could develop and
understand the risks associated with this. (A:III)
Patients with residual lagophthalmos must be told about the risk form exposure and
specifically warned about development of red eye and decreased vision. (A:III)
Patients should understand risks to eye during reaction and given explicit instructions on
where to report if reaction develops. (A:III)
All patients should be informed of significance of decreased vision and told to report this
to case worker for referral to higher level. (A:III)
Key sources
Grzybowski A, et al. Leprosy: ocular and systemic aspects. Clin Dermatol. 2016;34:24-31
World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. 2018
How to cite this page
Patel D. Eye Disease and Leprosy. RPC Rounds (Sadbhaav Eye Clinic). Updated October 2026. Available at: https://www.sadbhaavclinic.com/eyeleprosy.html. Accessed [date].
Written and medically reviewed by Dr. Dhaval Patel, MD (Ophthalmology, AIIMS New Delhi) · Editorial policy